Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 9:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–15 of 15 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Furosemide Injection Clear all
Terminated Phase 4 Interventional Results available

Compare the Diuretic Effect With Furosemide vs Furosemide and Albumin Combined in Cirrhotic Patients

NCT04216784
View directory record Official record
Conditions
Cirrhosis, Liver, Volume Overload, Fluid Overload
Interventions
Furosemide Injection, Albumin Human
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Sep 5, 2026, 9:05 PM EDT
Completed Phase 1 Interventional

Safety Study of ²¹²Pb-TCMC-Trastuzumab Radio Immunotherapy

NCT01384253
View directory record Official record
Conditions
Breast Neoplasms, Peritoneal Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms
Interventions
²¹²Pb-TCMC-Trastuzumab, trastuzumab
Other · Biological
Lead sponsor
Orano Med LLC
Industry
Eligibility
19 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
2
States / cities
Birmingham, Alabama • San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 29, 2016 · Synced Sep 5, 2026, 9:05 PM EDT
Terminated Phase 2 Interventional Results available

Subcutaneous Furosemide in Acute Decompensated Heart Failure: The SUBQ-HF Study

NCT03170219
View directory record Official record
Conditions
Acute Heart Failure, Decompensated Heart Failure
Interventions
subcutaneous furosemide and sc2wear device
Combination Product
Lead sponsor
Adrian Hernandez
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
16
States / cities
Atlanta, Georgia • Chicago, Illinois • Baltimore, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2019 · Synced Sep 5, 2026, 9:05 PM EDT
Completed Phase 2 Interventional Results available

Avoiding Treatment in the Hospital With Furoscix for the Management of Congestion in Heart Failure - A Pilot Study

NCT04593823
View directory record Official record
Conditions
Heart Failure
Interventions
Furoscix Infusor
Combination Product
Lead sponsor
scPharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
18
States / cities
Fairhope, Alabama • Huntsville, Alabama • Hartford, Connecticut + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2023 · Synced Sep 5, 2026, 9:05 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Crossover Study to Compare the Pharmacokinetics and Bioavailability of a Novel Furosemide Regimen Administered Subcutaneously vs. the Same Dose Administered Intravenously in Subjects With Chronic Heart Failure

NCT02329834
View directory record Official record
Conditions
Heart Failure
Interventions
Fursemide Injection Solution for subcutaneous administration (80 mg), Furosemide Injection, USP
Drug
Lead sponsor
scPharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
DeLand, Florida
Source: ClinicalTrials.gov public record
Updated Dec 1, 2022 · Synced Sep 5, 2026, 9:05 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Sub-Q Versus IV Furosemide in Acute Heart Failure

NCT02579057
View directory record Official record
Conditions
Congestive Heart Failure
Interventions
Furosemide Injection Solution (SCP-101), Furosemide Injection Solution, USP
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2017 · Synced Sep 5, 2026, 9:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetics and Pharmacodynamics of Subcutaneous vs Intravenous Furosemide in Healthy Volunteers

NCT06167707
View directory record Official record
Conditions
Heart Failure, Fluid Overload
Interventions
SCP-111, Furosemide USP
Drug
Lead sponsor
scPharmaceuticals, Inc.
Industry
Eligibility
45 Years to 80 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced Sep 5, 2026, 9:05 PM EDT
Completed Phase 2 Interventional Results available

Furoscix in Heart Failure Patients With Diuretic Resistance

NCT05528588
View directory record Official record
Conditions
Heart Failure
Interventions
Furoscix, Diuretic Therapy
Combination Product · Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2025 · Synced Sep 5, 2026, 9:05 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Crossover Study to Compare the Pharmacokinetics and Bioavailability of a Novel Furosemide Regimen Administered Subcutaneously vs. the Same Dose Administered Intravenously in Subjects With Chronic Heart Failure

NCT04384653
View directory record Official record
Conditions
Heart Failure
Interventions
Furosemide Injection Solution for subcutaneous administration (80 mg), Furosemide Injection, USP, Medfusion 3500 (v6) precision infusion pump
Drug · Device
Lead sponsor
SQ Innovation, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
DeLand, Florida
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Sep 5, 2026, 9:05 PM EDT
Withdrawn Phase 1Phase 2 Interventional

A Study to Investigate the Safety and Efficacy of a Novel Furosemide Regimen

NCT02721511
View directory record Official record
Conditions
Acute Decompensated Heart Failure
Interventions
Furosemide Injection Solution 8mg/mL
Drug
Lead sponsor
Todd M Koelling, MD
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 23, 2017 · Synced Sep 5, 2026, 9:05 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Evaluation of Renal Sodium Excretion After Salt Loading in Heart Failure With Preserved Ejection Fraction

NCT03837470
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
0.9% Sodium Chloride, Furosemide 40 mg
Drug
Lead sponsor
Adhish Agarwal
Other
Eligibility
21 Years to 80 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 18, 2021 · Synced Sep 5, 2026, 9:05 PM EDT
Completed Phase 4 Interventional Results available

Early Diuresis Following Colorectal Surgery

NCT02351934
View directory record Official record
Conditions
Colorectal Disorders
Interventions
Furosemide, Celecoxib, Gabapentin
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 6, 2018 · Synced Sep 5, 2026, 9:05 PM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

Intra-operative Loop Diuretics to Improve Same-day Discharge Rates After HoLEP

NCT05620784
View directory record Official record
Conditions
BPH With Urinary Obstruction, BPH, Hematuria, Same Day Discharge
Interventions
Furosemide
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 89 Years · Male only
Enrollment
138 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 12, 2023 · Synced Sep 5, 2026, 9:05 PM EDT
Not yet recruiting Phase 3 Interventional

Early Discharge With Subcutaneous Furosemide Versus Standard Care in Acute Heart Failure

NCT07018297
View directory record Official record
Conditions
Heart Failure, Acute Decompensated Heart Failure
Interventions
Early Discharge with Lasix® ONYU (furosemide injection, for subcutaneous use) using SQIN-Infusor
Combination Product
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 100 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Sep 5, 2026, 9:05 PM EDT
Completed Phase 3 Interventional Results available

Furoscix Real-World Evaluation for Decreasing Hospital Admissions in Heart Failure

NCT03458325
View directory record Official record
Conditions
Heart Failure
Interventions
Furoscix Infusor
Combination Product
Lead sponsor
scPharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
8
States / cities
Sylmar, California • Bridgeport, Connecticut • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2023 · Synced Sep 5, 2026, 9:05 PM EDT